1327 related articles for article (PubMed ID: 29649510)
1. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
5. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
6. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
7. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
8. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Qiu H; Shao Z; Wen X; Jiang J; Ma Q; Wang Y; Huang L; Ding X; Zhang L
Front Immunol; 2021; 12():716710. PubMed ID: 34539652
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade opens a new way to cancer immunotherapy.
Sadreddini S; Baradaran B; Aghebati-Maleki A; Sadreddini S; Shanehbandi D; Fotouhi A; Aghebati-Maleki L
J Cell Physiol; 2019 Jun; 234(6):8541-8549. PubMed ID: 30511409
[TBL] [Abstract][Full Text] [Related]
11. ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms.
Tian J; Ashique AM; Weeks S; Lan T; Yang H; Chen HH; Song C; Koyano K; Mondal K; Tsai D; Cheung I; Moshrefi M; Kekatpure A; Fan B; Li B; Qurashi S; Rocha L; Aguayo J; Rodgers C; Meza M; Heeke D; Medfisch SM; Chu C; Starck S; Basak NP; Sankaran S; Malhotra M; Crawley S; Tran TT; Duey DY; Ho C; Mikaelian I; Liu W; Rivera LB; Huang J; Paavola KJ; O'Hollaren K; Blum LK; Lin VY; Chen P; Iyer A; He S; Roda JM; Wang Y; Sissons J; Kutach AK; Kaplan DD; Stone GW
Cancer Immunol Res; 2024 May; 12(5):592-613. PubMed ID: 38393969
[TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to cancer immunotherapy.
Draghi A; Chamberlain CA; Furness A; Donia M
Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
[TBL] [Abstract][Full Text] [Related]
13. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
GarcĂa M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
15. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
18. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
[TBL] [Abstract][Full Text] [Related]
19. Novel Immunotherapy Combinations.
Bashir B; Wilson MA
Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
[TBL] [Abstract][Full Text] [Related]
20. The role of exosomal PD-L1 in tumor progression and immunotherapy.
Xie F; Xu M; Lu J; Mao L; Wang S
Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]